1. Home
  2. SNGX vs ASBP Comparison

SNGX vs ASBP Comparison

Compare SNGX & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.46

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Logo Aspire Biopharma Holdings Inc.

ASBP

Aspire Biopharma Holdings Inc.

HOLD

Current Price

$0.12

Market Cap

15.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
ASBP
Founded
1987
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
15.0M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
SNGX
ASBP
Price
$1.46
$0.12
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
455.1K
17.4M
Earning Date
11-07-2025
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,941.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$0.07
52 Week High
$6.23
$15.80

Technical Indicators

Market Signals
Indicator
SNGX
ASBP
Relative Strength Index (RSI) 52.13 49.95
Support Level $1.31 $0.09
Resistance Level $1.45 $0.15
Average True Range (ATR) 0.10 0.01
MACD 0.00 0.01
Stochastic Oscillator 57.45 52.10

Price Performance

Historical Comparison
SNGX
ASBP

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About ASBP Aspire Biopharma Holdings Inc.

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

Share on Social Networks: